Clinical Trials Logo
  1. Home
  2. Myotonic Dystrophy Type 1
  3. NCT05916677

Virtual Reality-training in Theory of Mind in the Childhood Form of Myotonic Dystrophy Type 1 — TOM-VR-DM1  

Myotonic Dystrophy Type 1 Clinical Trial

Official title:
Virtual Reality-training in Theory of Mind in the Childhood Form of Myotonic Dystrophy Type 1

Clinical Trial Summary

The ability of an individual to conceive some alternative representations and to behave in a flexible manner would emerge from preschool age and drastically improve between the ages of 3 and 5 (Doebel and Zelazo, 2013). They constitute, according to Diamond (2013), a prerequisite for the development of the Theory of Mind (ToM). Deficits in Executive Functions (EF) may therefore interfere with the child's ability to understand and adapt to social situations. Treatment failures are often observed when traditional cognitive tools are used. This would be linked to the divergence between non-immersive tests and situations encountered in everyday life (Damasio, 1994; Priore Castelnuovo and Liccione, 2002). For this reason, an increasing number of researchers are using virtual reality for the rehabilitation of executive functions and Theory of Mind in patients with neurodevelopmental pathology (Millen, Edlin-White and Cobb, 2010) or brain damage (Le Gall, Besnard, Louisy, Richard and Allain 2008). There is currently no systematic evaluation of ToM in children with the infantile form of DM1 even though these abilities are considered particularly vulnerable and have a decisive impact on the subsequent development of interpersonal relationships. This research will focus on studying the socio-emotional disorders associated with the infantile form of Myotonic Dystrophy type 1 (DM1). The axis that we propose to develop more specifically will be an interventional study with the aim of remediation with children from 5 to 16 years old suffering from the infantile form of DM1 via a training protocol in low-immersion Virtual Reality (VR) centered on emotional processing and theory of mind.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05916677
Study type Interventional
Source Institut de Myologie, France
Contact
Status Enrolling by invitation
Phase N/A
Start date October 30, 2023
Completion date July 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT00082108 - Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Completed NCT02308657 - Multicenter Observational Study of Myotonic Dystrophy Type 1 N/A
Enrolling by invitation NCT06316778 - Pelvic Floor Muscle Training for Women With Myotonic Dystrophy N/A
Completed NCT02312011 - A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Phase 1/Phase 2
Recruiting NCT02269865 - Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy N/A
Completed NCT00577577 - Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 Phase 2
Completed NCT02831504 - PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study)
Recruiting NCT06075693 - Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Completed NCT02118779 - Observational Prolonged Trial in Myotonic Dystrophy Type 1 N/A